Suffering

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

Thursday, March 4, 2021 - 8:30am

Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.

Key Points: 
  • Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.
  • "PsyCollage ensures we are moving in the right direction in our mission to provide alternative and effective treatment options for psychological and physiological pain," said Kelsey Ramsden, President & CEO, MINDCURE.
  • "Ibogaine has centuries of therapeutic history reinforcing its potential to heal pain.
  • MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health.

Worldwide Industry for Pharmaceutical Treatments for Mental Health Disorders to 2025 - Snapshot of Products in Phase III Development for Selected Psychiatric Disorders

Friday, February 26, 2021 - 8:00pm

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Pharmaceutical Treatments for Mental Health Disorders: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Pharmaceutical Treatments for Mental Health Disorders: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry.
  • Mental health disorders refer to a wide range of mental health disorders that affect mood, thinking and behavior.
  • Reasons for Doing This Study:
    The treatment of mental health disorders is complex and often involves pharmacological and behavioral interventions.

Emory University’s Compassion Center Announces Plans for Global 21-Day Compassion Challenge That Begins March 6, 2021

Thursday, February 25, 2021 - 2:36pm

Emory Universitys Center for Contemplative Science and Compassion-Based Ethics, with the support of His Holiness The Dalai Lama, will kick off a 21-Day Compassion Challenge March 6, 2021.

Key Points: 
  • Emory Universitys Center for Contemplative Science and Compassion-Based Ethics, with the support of His Holiness The Dalai Lama, will kick off a 21-Day Compassion Challenge March 6, 2021.
  • The 21-Day Compassion Challenge is designed to help people recognize their capacity for compassion and learn how to practice it daily.
  • Over the course of three weeks, participants progress sequentially through a series of topics that explore the transformative power of compassion.
  • Cultivating compassion toward self and others is the urgent need of our time, said Lobsang Tenzin Negi, executive director of the Compassion Center.

Global Pharmaceutical Treatments for Mental Health Disorders Market (2020 to 2025) - Conditions are Likely to Rise in the Near Future Due to the Consequences of COVID-19 - ResearchAndMarkets.com

Wednesday, February 24, 2021 - 4:37pm

Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth

Key Points: 
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
    Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COVID-19 pandemic, social distancing and social isolation on the mental health conditions
    A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
    Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
    Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
    Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
    Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
    Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COVID-19 pandemic, social distancing and social isolation.

Life Clips to Acquire Mental Health Voice-Based AI Technology Company

Wednesday, February 24, 2021 - 1:40pm

Dr. Manideep Gopishetty, CEO and Co-founder of Cognitive Apps, said, "Our advanced voice recognition AI technology diagnostic core can identify various mental health disorders.

Key Points: 
  • Dr. Manideep Gopishetty, CEO and Co-founder of Cognitive Apps, said, "Our advanced voice recognition AI technology diagnostic core can identify various mental health disorders.
  • With the acquisition, Life Clips gains access to Cognitive Apps' intellectual property, including AI enabled speech-based technology, and its research and development team.
  • Life Clips will further develop Cognitive Apps' technology for use in the development and testing of psychedelics for the treatment of various mental health disorders.
  • "Our mission is to make Life Clips a digital medicine company capable of disrupting the way data is captured and measured for various mental health disorders in modern healthcare.

National Spine and Pain Centers Names Douglas Badertscher President

Tuesday, February 23, 2021 - 6:12pm

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.
  • Most recently, Badertscher served as President and COO of Pain Specialists of America.
  • About National Spine and Pain Centers:
    For more than 30 years, NSPC affiliated physicians have been pioneers in the relief of chronic and acute pain through minimally invasive procedures and leading-edge clinical research.
  • Medical services provided by independently operated physician practices branded as National Spine and Pain Centers and other affiliated brands.

PureHA Puts the Brakes on the Aging Process

Monday, February 22, 2021 - 1:44pm

FORT LAUDERDALE, Fla., Feb. 22, 2021 /PRNewswire/ --The aging process comes with a variety of side effects.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 22, 2021 /PRNewswire/ --The aging process comes with a variety of side effects.
  • That's why Canadian health and wellness brand Revelox had everything from cosmetics to pain-relief in mind when they created PureHA.
  • PureHA addresses external aging concerns by rejuvenating skin and helping to promote the overall health of the body's largest organ.
  • PureHA has received positive reviews, with one even claiming that significant herniated pain was completely relieved "after only a week of taking PureHA."

2021 Pipeline Insights on the Postoperative Pain Industry - ResearchAndMarkets.com

Wednesday, February 17, 2021 - 2:08pm

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape.
  • "Postoperative pain - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Postoperative pain pipeline landscape is provided which includes the disease overview and Postoperative pain treatment guidelines.
  • Postoperative pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing

Wednesday, February 17, 2021 - 1:55pm

Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.

Key Points: 
  • Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.
  • Traumatic brain injuries are a major cause of death and disability in North America and are increasing in number.
  • As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together.
  • Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing

Wednesday, February 17, 2021 - 1:55pm

Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.

Key Points: 
  • Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.
  • Traumatic brain injuries are a major cause of death and disability in North America and are increasing in number.
  • As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together.
  • Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.